Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight
Part of paid clinical trials in Avondale, Arizona.
- Sponsor
- Eli Lilly and Company
- Study ID
- NCT06588296
- Phase
- PHASE3
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 80 Years
- Healthy Volunteers
- Not accepted
Interventions
- Ixekizumab — DRUGAdministered SC
- Tirzepatide — DRUGAdministered SC
Study Details
The main purpose of this study is to demonstrate that when participants with psoriatic arthritis and obesity or overweight in the presence of at least 1 weight-related comorbid condition receive ixekizumab and tirzepatide concomitantly administered, participants see improvement in their psoriatic arthritis and achieve weight reduction compared to when receiving ixekizumab. Participation in this study includes up to 12 visits and could last up to 61 weeks including screening, open label treatment period, and post-treatment follow-up period.
Key Dates
- Start date
- Sep 24, 2024
- Status verified
- May 2026
- Primary completion
- Nov 18, 2025
- Completion
- Apr 23, 2026
Study Design
- Enrollment
- 279 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: IxekizumabIxekizumab administered subcutaneous (SC).
- Experimental: Ixekizumab and TirzepatideIxekizumab concomitantly administered with tirzepatide SC.
Primary Outcome Measure
Percentage of Participants Who Simultaneously Achieved American College of Rheumatology (ACR) ACR50 and at Least a 10% Weight Reduction [ Time Frame: Baseline up to Week 36 ]
Locations (81)
Related coverage on Hipa.ai
- Ixekizumab + Tirzepatide Phase 3 Trial for Psoriatic Arthritis & Obesity…Ixekizumab · Nov 18, 2025 · ClinicalTrials.gov
Find similar trials in Avondale, AZ
Related Studies
- Diabetes and Heart Disease Risk in BlacksRecruiting · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Bethesda, Maryland
- Physical and Behavioral Traits of Overweight and Obese AdultsRecruiting · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Bethesda, Maryland
- Effects of Brain Stimulation on Food Intake and Behavioral Weight Loss TreatmentPHASE2 · Recruiting · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Phoenix, Arizona
- Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular SystemRecruiting · National Heart, Lung, and Blood Institute (NHLBI) · Washington D.C., District of Columbia